Alnylam Pharmaceuticals
ALNY
$148.50
Share price
0.34%
Change (1 day)
-10.74%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Market capitalization of Alnylam Pharmaceuticals (ALNY)
Market cap: $17.76 Billion
As of January 2022 Alnylam Pharmaceuticals has a market cap of $17.76 Billion. This makes Alnylam Pharmaceuticals the world's 1041th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to mesure how much a company is worth.
Market cap history of Alnylam Pharmaceuticals from 2004 to 2022
| Year | Market cap | Change |
|---|---|---|
| 2022 | $17.76 B | -23.59% |
| 2021 | $23.24 B | 53.94% |
| 2020 | $15.10 B | 16.87% |
| 2019 | $12.92 B | 75.15% |
| 2018 | $7.37 B | -41.45% |
| 2017 | $12.59 B | 292.16% |
| 2016 | $3.21 B | -59.89% |
| 2015 | $8.01 B | 6.97% |
| 2014 | $7.48 B | 82.71% |
| 2013 | $4.09 B | 327.85% |
| 2012 | $0.95 B | 175.09% |
| 2011 | $0.34 B | -16.59% |
| 2010 | $0.41 B | -43.36% |
| 2009 | $0.73 B | -28.02% |
| 2008 | $1.02 B | -13.62% |
| 2007 | $1.18 B | 49.54% |
| 2006 | $0.79 B | 207.77% |
| 2005 | $0.25 B | 78.85% |
| 2004 | $0.14 B |
End of Day market cap according to different sources
On Jan 17th, 2022 the market cap of Alnylam Pharmaceuticals was reported to be:
$17.76 Billion
$17.76 Billion
$17.76 Billion
$17.76 Billion
$17.76 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap difference | Country |
|---|---|---|---|
 Novartis NVS | $202.56 B | 1,040.54% | 🇨🇭 Switzerland |
 Sanofi SNY | $130.37 B | 634.06% | 🇫🇷 France |
 Regeneron Pharmaceuticals REGN | $66.16 B | 272.53% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | $6.19 B | -65.14% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | $0.03 B | -99.80% | 🇺🇸 USA |
 OPKO Health
OPK | $3.08 B | -82.62% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $10.17 B | -42.69% | 🇮🇱 Israel |
 Arrowhead Pharmaceuticals
ARWR | $6.04 B | -65.98% | 🇺🇸 USA |